Hematologic malignancies: An opportunity for targeted drug therapy

被引：0

作者：

Gabrilove, JL ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Dept Med, Div Med Oncol, New York, NY 10029 USA

[2] Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA

来源：

ONCOLOGIST | 2001年 / 6卷

关键词：

cancer; leukemia; myelodysplastic syndromes; chemotherapy angiogenesis; thrombocytopenia;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 3

页数：3

共 18 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Oncogenic kinase signalling [J].

Blume-Jensen, P ;

Hunter, T .

NATURE, 2001, 411 (6835) :355-365

[3]

Burger JA, 2000, BLOOD, V96, P2655

[4]

Carter S K, 2000, Oncologist, V5 Suppl 1, P51

[5]

Demetri GD, 2001, ONCOLOGIST, V6, P15

[6]

Devita Vincent T. Jr., 1997, P333

[7] The rationale and future potential of angiogenesis inhibitors in neoplasia [J].

Gasparini, G .

DRUGS, 1999, 58 (01) :17-38

[8]

Giles FJ, 2001, ONCOLOGIST, V6, P32

[9] The hallmarks of cancer [J].

Hanahan, D ;

Weinberg, RA .

CELL, 2000, 100 (01) :57-70

[10] Signaling - 2000 and beyond [J].

Hunter, T .

CELL, 2000, 100 (01) :113-127

← 1 2 →